PGNY vs. HQY: Which Stock Offers Better Value?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy PGNY?
Source: NASDAQ.COM
Comparison of Stocks: Progyny (PGNY) has a stronger Zacks Rank (#2) compared to HealthEquity (HQY) (#3), indicating better earnings estimate revisions and a more favorable analyst outlook for value investors.
Valuation Metrics: PGNY boasts a forward P/E ratio of 13.82 and a PEG ratio of 0.83, while HQY has a forward P/E of 25.75 and a PEG ratio of 1.19, making PGNY appear more attractive based on traditional valuation metrics.
Value Grades: PGNY has received a Value grade of B, whereas HQY has a grade of D, further supporting the notion that PGNY is the superior choice for value investors at this time.
Investment Recommendations: Zacks Investment Research has identified five stocks with high potential for significant gains, including a satellite-based communications firm expected to thrive in the growing trillion-dollar space industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PGNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PGNY
Wall Street analysts forecast PGNY stock price to rise
8 Analyst Rating
6 Buy
2 Hold
0 Sell
Strong Buy
Current: 17.520
Low
26.00
Averages
29.75
High
34.00
Current: 17.520
Low
26.00
Averages
29.75
High
34.00
About PGNY
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Company’s clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.7 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a member’s full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Progyny Reports Record Revenue and EBITDA for 2025
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
See More
Progyny Releases 2026 Financial Outlook with Strong Q4 Results
- Earnings Beat: Progyny reported a Q4 non-GAAP EPS of $0.48, exceeding expectations by $0.08, with revenue of $318.4 million reflecting a 6.7% year-over-year increase, surpassing estimates by $4.14 million, indicating strong market performance.
- 2026 Outlook: The company projects 2026 revenue between $1.355 billion and $1.405 billion, representing growth of 5.1% to 9.0%; excluding $48.5 million from a large client in 2025, expected growth rises to 9.3% to 13.3%, showcasing optimism for future performance.
- Net Income Projections: Net income for 2026 is anticipated to be between $95.4 million and $106.1 million, translating to diluted EPS of $1.10 to $1.22 based on approximately 87 million shares, reflecting sustained profitability improvements.
- Adjusted EBITDA Forecast: Adjusted EBITDA is projected to range from $224 million to $239 million, with adjusted EPS expected between $1.83 and $1.95, highlighting effective cost management and profitability enhancement strategies.
See More
Progyny (PGNY) to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Progyny (PGNY) is set to announce its Q4 2023 earnings on February 26 after market close, with a consensus EPS estimate of $0.40, reflecting a 4.8% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $314.26 million, representing a 5.3% year-over-year increase, indicating the company's ongoing growth potential in the fertility health sector despite the slight EPS decline.
- Historical Performance: Over the past two years, Progyny has exceeded EPS estimates 100% of the time and revenue estimates 50% of the time, demonstrating the company's stability and reliability in financial performance.
- Revision Trends: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, and revenue estimates have also experienced two upward revisions, reflecting analysts' optimistic outlook on the company's future performance.
See More
Progyny to Report Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Progyny will report its quarterly and full-year financial results for the period ending December 31, 2025, after market close on February 26, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 4:45 p.m. Eastern Time, providing a detailed discussion of its financial results, which is expected to attract significant attention from investors and analysts, thereby enhancing market confidence.
- International Participation: U.S. participants can dial 1.866.825.7331, while international participants can call 1.973.413.6106, using the same passcode 265484, ensuring that global investors can engage in the discussion and enhancing the company's international profile.
- Replay and Webcast: An audio replay of the call will be available until March 5, 2026, and can be accessed via the Events and Presentations section of the company's website, reflecting the company's commitment to information sharing.
See More
Goldman Sachs Upgrades Enphase Energy to Buy, Raises Target to $45
- Analyst Rating Upgrade: Goldman Sachs analyst Brian Lee upgraded Enphase Energy (NASDAQ:ENPH) from Neutral to Buy and raised the price target from $29 to $45, reflecting confidence in its future growth potential.
- Intel Rating Adjustment: HSBC analyst Frank Lee upgraded Intel (NASDAQ:INTC) from Reduce to Hold and increased the price target from $26 to $50, indicating expectations for improved market performance.
- Progyny Market Performance Improvement: Citizens analyst Constantine Davides upgraded Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and set a price target of $30, suggesting optimism about its business growth.
- Brinker International Rating Upgrade: Morgan Stanley analyst John Glass upgraded Brinker International (NYSE:EAT) from Equal-Weight to Overweight and raised the price target from $160 to $200, reflecting a positive outlook on its future profitability.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
Progyny Reports Record Revenue and EBITDA for 2025
- Record Financial Performance: Progyny achieved $1.29 billion in revenue and $222 million in adjusted EBITDA for 2025, exceeding the midpoint of original guidance by nearly $90 million and $28 million respectively, showcasing the company's robust market performance and profitability.
- Strong Cash Flow Growth: The operating cash flow reached a record $210 million in 2025, reflecting a 17% increase over 2024, which provides strong support for future investments and shareholder returns, further solidifying the company's financial health.
- Near 100% Client Retention: Progyny reported nearly 100% client retention among large employers, with 30% of clients expanding benefits for 2026, indicating sustained competitiveness and high customer satisfaction in the market.
- New Product Strategic Launch: The introduction of Progyny Select targets the needs of 50 million smaller employers, expected to contribute new revenue streams in 2027, marking a strategic shift in the company's focus and further expanding its market share.
See More
Progyny Releases 2026 Financial Outlook with Strong Q4 Results
- Earnings Beat: Progyny reported a Q4 non-GAAP EPS of $0.48, exceeding expectations by $0.08, with revenue of $318.4 million reflecting a 6.7% year-over-year increase, surpassing estimates by $4.14 million, indicating strong market performance.
- 2026 Outlook: The company projects 2026 revenue between $1.355 billion and $1.405 billion, representing growth of 5.1% to 9.0%; excluding $48.5 million from a large client in 2025, expected growth rises to 9.3% to 13.3%, showcasing optimism for future performance.
- Net Income Projections: Net income for 2026 is anticipated to be between $95.4 million and $106.1 million, translating to diluted EPS of $1.10 to $1.22 based on approximately 87 million shares, reflecting sustained profitability improvements.
- Adjusted EBITDA Forecast: Adjusted EBITDA is projected to range from $224 million to $239 million, with adjusted EPS expected between $1.83 and $1.95, highlighting effective cost management and profitability enhancement strategies.
See More
Progyny (PGNY) to Announce Q4 Earnings on February 26
- Earnings Announcement Date: Progyny (PGNY) is set to announce its Q4 2023 earnings on February 26 after market close, with a consensus EPS estimate of $0.40, reflecting a 4.8% year-over-year decline, which may impact investor sentiment.
- Revenue Growth Expectations: The anticipated revenue for Q4 is $314.26 million, representing a 5.3% year-over-year increase, indicating the company's ongoing growth potential in the fertility health sector despite the slight EPS decline.
- Historical Performance: Over the past two years, Progyny has exceeded EPS estimates 100% of the time and revenue estimates 50% of the time, demonstrating the company's stability and reliability in financial performance.
- Revision Trends: In the last three months, EPS estimates have seen two upward revisions with no downward adjustments, and revenue estimates have also experienced two upward revisions, reflecting analysts' optimistic outlook on the company's future performance.
See More
Progyny to Report Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Progyny will report its quarterly and full-year financial results for the period ending December 31, 2025, after market close on February 26, 2026, demonstrating the company's commitment to transparency and investor communication.
- Conference Call Details: The company will host a conference call at 4:45 p.m. Eastern Time, providing a detailed discussion of its financial results, which is expected to attract significant attention from investors and analysts, thereby enhancing market confidence.
- International Participation: U.S. participants can dial 1.866.825.7331, while international participants can call 1.973.413.6106, using the same passcode 265484, ensuring that global investors can engage in the discussion and enhancing the company's international profile.
- Replay and Webcast: An audio replay of the call will be available until March 5, 2026, and can be accessed via the Events and Presentations section of the company's website, reflecting the company's commitment to information sharing.
See More
Goldman Sachs Upgrades Enphase Energy to Buy, Raises Target to $45
- Analyst Rating Upgrade: Goldman Sachs analyst Brian Lee upgraded Enphase Energy (NASDAQ:ENPH) from Neutral to Buy and raised the price target from $29 to $45, reflecting confidence in its future growth potential.
- Intel Rating Adjustment: HSBC analyst Frank Lee upgraded Intel (NASDAQ:INTC) from Reduce to Hold and increased the price target from $26 to $50, indicating expectations for improved market performance.
- Progyny Market Performance Improvement: Citizens analyst Constantine Davides upgraded Progyny (NASDAQ:PGNY) from Market Perform to Market Outperform and set a price target of $30, suggesting optimism about its business growth.
- Brinker International Rating Upgrade: Morgan Stanley analyst John Glass upgraded Brinker International (NYSE:EAT) from Equal-Weight to Overweight and raised the price target from $160 to $200, reflecting a positive outlook on its future profitability.
See More
